Preliminary validation of the pica, ARFID and rumination disorder interview ARFID questionnaire (PARDI-AR-Q).

Autor: Bryant-Waugh R; South London and Maudsley NHS Foundation Trust, London, UK.; Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK., Stern CM; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA., Dreier MJ; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Department of Psychology, Rutgers University, Piscataway, USA., Micali N; Department of Psychiatry, University of Geneva, Geneva, Switzerland.; Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.; Eating Disorders Research Unit, Mental Health Center Ballerup, Mental Health Services of the Capital Region of Denmark, Ballerup, Denmark., Cooke LJ; Great Ormond Street Hospital for Children NHS Trust, London, UK., Kuhnle MC; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Department of Epidemiology, Boston University, Boston, USA., Burton Murray H; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Center for Neurointestinal Health, Massachusetts General Hospital, Boston, USA.; Harvard Medical School, Boston, USA., Wang SB; Department of Psychology, Harvard University, Cambridge, USA., Breithaupt L; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Harvard Medical School, Boston, USA.; Department of Psychiatry, Athinoula A. Martinos Center for Biomedical Imaging, Boston, USA., Becker KR; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Harvard Medical School, Boston, USA., Misra M; Harvard Medical School, Boston, USA.; Neuroendocrine Unit, Massachusetts General Hospital, Boston, USA., Lawson EA; Harvard Medical School, Boston, USA.; Neuroendocrine Unit, Massachusetts General Hospital, Boston, USA., Eddy KT; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA.; Harvard Medical School, Boston, USA., Thomas JJ; Eating Disorders Clinical and Research Program, Massachusetts General Hospital, 2 Longfellow Place, Suite 200, Boston, MA, 02114, USA. jjthomas@mgh.harvard.edu.; Harvard Medical School, Boston, USA. jjthomas@mgh.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of eating disorders [J Eat Disord] 2022 Nov 22; Vol. 10 (1), pp. 179. Date of Electronic Publication: 2022 Nov 22.
DOI: 10.1186/s40337-022-00706-7
Abstrakt: Background: The Pica, ARFID, and Rumination Disorder Interview (PARDI) is a structured interview that can be used to determine diagnosis, presenting characteristics, and severity across three disorders, including avoidant/restrictive food intake disorder (ARFID). The purpose of this study was to evaluate the psychometric properties of a questionnaire focused specifically on ARFID (PARDI-AR-Q), which has the potential to provide related information with less participant burden.
Methods: Adolescents and adults (n = 71, ages 14-40 years) with ARFID (n = 42) and healthy control participants (HC, n = 29) completed the PARDI-AR-Q and other measures. A subset of the ARFID group (n = 27) also completed the PARDI interview.
Results: An exploratory factor analysis of proposed subscale items identified three factors corresponding to the ARFID phenotypes of avoidance based on the sensory characteristics of food, lack of interest in eating or food, and concern about aversive consequences of eating. Further analyses supported the internal consistency and convergent validity of the PARDI-AR-Q subscales, and subscale ratings on the questionnaire showed large and significant correlations (all p-values < 0.001; r's ranging from 0.48 to 0.77) with the corresponding subscales on the interview. The ARFID group scored significantly higher than HC on all subscales. Furthermore, 90% of the ARFID group scored positive on the PARDI-AR-Q diagnostic algorithm while 93% of the HC scored negative.
Conclusions: Though replication in larger and more diverse samples is needed, findings provide early support for the validity of the PARDI-AR-Q as a self-report measure for possible ARFID in clinical or research settings.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje